Objective<\/strong>: The aim of this study is to evaluate the effectiveness of daptomycin (DAP) in neutropenic patients with haematological malignancies.<\/p>\n Methods<\/strong>: We evaluated data of neutropenic patients treated with DAP in adult haematology unit of our hospital between January 2011 and April 2013. Neutropenia was classified as severe (<100\/mm3), moderate (101-499\/mm3), and mild (500-1000\/mm3). Clinical outcomes included cure, improved, failed and nonevaluable response. Clinical success described patients with an outcome of cure or improved.<\/p>\n Results<\/strong>: 43 neutropenic patients who used DAP were identified. All had haematological malignancies and 21 (48.8%) had severe neutropenia. 40 (93%) patients received antibiotics prior to DAP. Skin and soft tissue infections (75%) were the most common diagnosis. Gram-positive organisms were identified only in 12 (27.9%) patients. Enterococcus faecium was the most common Gram-positive pathogen (n=7). The initial dose of DAP was 6 mg\/kg in all patients and the median duration of therapy was 15.5 days (range 2-45). Overall clinical success was 82.5% (33\/40). Clinical success rates were 84%, 72% and 90% in severe, moderate and mild neutropenic patients, respectively. The success rate in patients receiving DAP as first-line therapy was 100% (12\/12) compared with 75% (21\/28) success rate in patients who received DAP as second-line therapy. Success rates were 83% for bacteremia and 81% for skin and soft tissue infections. No adverse event related to DAP was reported.<\/p>\n Conclusions<\/strong>: Our data indicate that DAP is effective as first- and second-line therapy in the treatment of neutropenic patients with haematological malignancies.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":" Abstract Objective: The aim of this study is to evaluate the effectiveness of daptomycin (DAP) in neutropenic patients with haematological malignancies. Methods: We evaluated data of neutropenic patients treated with DAP in adult haematology unit of our hospital between January 2011 and April 2013. Neutropenia was classified as severe (<100\/mm3), moderate (101-499\/mm3), and mild (500-1000\/mm3). […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5130],"tags":[3988,4467,4465,2992],"class_list":["post-15468","post","type-post","status-publish","format-standard","hentry","category-original-article","tag-daptomycin","tag-grampositive-bacterial-infections","tag-haematologic-neoplasms","tag-neutropenia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/15468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/comments?post=15468"}],"version-history":[{"count":0,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/posts\/15468\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/media?parent=15468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/categories?post=15468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimikdergisi.org\/en\/wp-json\/wp\/v2\/tags?post=15468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}